StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)

Close on Nov 16, 2026Market cap $303.43MP/E –Yield –

Autolus Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Autolus Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$238.85M. For fiscal 2025 it was -$262.25M. The highest annual figure on record is -$132.59M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$262.25M–
FY2024Dec 31, 2024-$233.87M–
FY2023Dec 31, 2023-$173.14M–
FY2022Dec 31, 2022-$135.99M–
FY2021Dec 31, 2021-$132.59M–
FY2020Dec 31, 2020-$162.49M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$41.68M–
Q1 FY2026CQ1 2026Mar 31, 2026-$57.30M–
Q4 FY2025CQ4 2025Dec 31, 2025-$70.32M–
Q3 FY2025CQ3 2025Sep 30, 2025-$69.54M–
Q2 FY2025CQ2 2025Jun 30, 2025-$59.13M–
Q1 FY2025CQ1 2025Mar 31, 2025-$63.25M–
Q4 FY2024CQ4 2024Dec 31, 2024-$73.95M–
Q3 FY2024CQ3 2024Sep 30, 2024-$65.94M–
Q2 FY2024CQ2 2024Jun 30, 2024-$57.03M–
Q1 FY2024CQ1 2024Mar 31, 2024-$36.95M–
Q4 FY2023CQ4 2023Dec 31, 2023-$51.50M–
Q3 FY2023CQ3 2023Sep 30, 2023-$41.53M–
Q2 FY2023CQ2 2023Jun 30, 2023-$42.87M–
Q1 FY2023CQ1 2023Mar 31, 2023-$37.25M–
Q4 FY2022CQ4 2022Dec 31, 2022-$10.00M–
Q1 FY2021CQ1 2021Mar 31, 2021-$38.21M–
Q4 FY2020CQ4 2020Dec 31, 2020-$45.67M–
Q3 FY2020CQ3 2020Sep 30, 2020-$41.24M–
Q2 FY2020CQ2 2020Jun 30, 2020-$38.28M–
Q1 FY2020CQ1 2020Mar 31, 2020-$37.30M–

More Autolus Therapeutics figures

See a number that looks wrong?